Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
Tenaya Therapeutics (NASDAQ: TNYA) announced that CEO Faraz Ali will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on October 14, 2025. Company management will hold virtual 1x1 meetings on October 15, 2025. The fireside chat will be webcast and accessible from the Investors section of Tenaya's website, with an archived replay available for approximately 30 days after the conference.
Tenaya Therapeutics (NASDAQ: TNYA) ha annunciato che il CEO Faraz Ali parteciperà a un colloquio informale durante la conferenza virtuale di H.C. Wainwright Genetic Medicines il 14 ottobre 2025. La direzione dell'azienda terrà incontri virtuali one-to-one il 15 ottobre 2025. Il colloquio informale sarà trasmesso in streaming e accessibile dalla sezione Investitori del sito di Tenaya, con una riproduzione archiviata disponibile per circa 30 giorni dopo la conferenza.
Tenaya Therapeutics (NASDAQ: TNYA) anunció que el CEO Faraz Ali participará en una charla junto a la chimenea en la Conferencia Virtual de Medicinas Genéticas de H.C. Wainwright el 14 de octubre de 2025. La dirección de la empresa llevará a cabo reuniones virtuales 1x1 el 15 de octubre de 2025. La charla junto a la chimenea será transmitida en directo y estará accesible desde la sección de Inversores del sitio web de Tenaya, con una repetición archivada disponible durante aproximadamente 30 días después de la conferencia.
Tenaya Therapeutics(NASDAQ: TNYA)는 CEO Faraz Ali가 H.C. Wainwright 유전의학 가상 컨퍼런스에서 2025년 10월 14일에 좌담회에 참여할 것이라고 발표했습니다. 회사 경영진은 2025년 10월 15일에 가상 1대1 회의를 개최합니다. 좌담회는 생중계로 진행되며 Tenaya의 웹사이트 투자자 섹션에서 접근 가능하고, 컨퍼런스 후 약 30일간 아카이브 재생이 제공됩니다.
Tenaya Therapeutics (NASDAQ : TNYA) a annoncé que le PDG Faraz Ali participera à une discussion informelle lors de la conférence virtuelle sur les médicaments génétiques de H.C. Wainwright le 14 octobre 2025. La direction de l'entreprise tiendra des réunions virtuelles en tête-à-tête le 15 octobre 2025. La discussion informelle sera diffusée en direct et sera accessible depuis la section Investors du site Web de Tenaya, avec une reproduction archivisée disponible pendant environ 30 jours après la conférence.
Tenaya Therapeutics (NASDAQ: TNYA) gab bekannt, dass CEO Faraz Ali an einer Fireside-Chats bei der H.C. Wainwright Virtual Conference über Genmedizin am 14. Oktober 2025 teilnehmen wird. Das Management des Unternehmens wird am 15. Oktober 2025 virtuelle 1:1-Meetings abhalten. Der Fireside-Chat wird gestreamt und ist im Bereich Investorenseite von Tenaya's Website zugänglich, mit einer archivierten Wiedergabe für ca. 30 Tage nach der Konferenz.
أعلنت Tenaya Therapeutics (بورصة ناسداك: TNYA) أن الرئيس التنفيذي فاراز علي سيشارك في جلسة حوارية خلال المؤتمر الافتراضي للأدوية الجينية من H.C. Wainwright في 14 أكتوبر 2025. سيعقد فريق الإدارة اجتماعات افتراضية فردية في 15 أكتوبر 2025. ستُبث جلسة الحوار عبر الإنترنت وتكون متاحة من قسم المستثمرين في موقع Tenaya على الويب، مع إمكانية مشاهدة إعادة أرشيفية لمدة حوالي 30 يومًا بعد المؤتمر.
Tenaya Therapeutics（纳斯达克股票代码：TNYA）宣布首席执行官 Faraz Ali 将在 H.C. Wainwright 基因治疗药物虚拟会议 上参加 2025年10月14日 的炉边对谈。公司管理层将于 2025年10月15日 举行虚拟的一对一会晤。炉边对谈将进行网络直播，并可通过 Tenaya 网站的投资者栏目访问，会议结束后大约30天内提供存档回放。
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on Tuesday, October 14, 2025. Company management will host virtual 1x1 meetings on Wednesday, October 15, 2025.
The webcast of the fireside chat may be accessed from the Investors section of Tenaya’s website. An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
FAQ
When will Tenaya Therapeutics (TNYA) present at the H.C. Wainwright conference?
How can investors watch Tenaya Therapeutics (TNYA) fireside chat on October 14, 2025?
Will Tenaya Therapeutics (TNYA) provide a replay of the October 14, 2025 webcast?
Who from Tenaya Therapeutics will speak at the H.C. Wainwright Genetic Medicines event?
Will Tenaya Therapeutics (TNYA) host investor meetings at the conference?
Where can I find details and scheduling for Tenaya Therapeutics (TNYA) conference participation?
